Corneal collagen crosslinking (CXL) has been proposed as an effective method of reducing
progression of both keratoconus and corneal ectasia after surgery, as well as possibly
decreasing the steepness of the cornea in these pathologies. During previous studies of the
CXL procedure, the surface epithelial cells have been removed. Transepithelial crosslinking
in which the epithelium is not removed has been proposed to offer a number of advantages over
traditional crosslinking including an increased safety profile by reducing the risk for
infection as no epithelial barrier will be broken, faster visual recovery and improved
patient comfort in the early postoperative healing period.